Literature DB >> 35794200

Lung microbial-host interface through the lens of multi-omics.

Shivani Singh1, Jake G Natalini1,2, Leopoldo N Segal3.   

Abstract

In recent years, our understanding of the microbial world within us has been revolutionized by the use of culture-independent techniques. The use of multi-omic approaches can now not only comprehensively characterize the microbial environment but also evaluate its functional aspects and its relationship with the host immune response. Advances in bioinformatics have enabled high throughput and in-depth analyses of transcripts, proteins and metabolites and enormously expanded our understanding of the role of the human microbiome in different conditions. Such investigations of the lower airways have specific challenges but as the field develops, new approaches will be facilitated. In this review, we focus on how integrative multi-omics can advance our understanding of the microbial environment and its effects on the host immune tone in the lungs.
© 2022. The Author(s), under exclusive licence to Society for Mucosal Immunology.

Entities:  

Mesh:

Year:  2022        PMID: 35794200      PMCID: PMC9391302          DOI: 10.1038/s41385-022-00541-8

Source DB:  PubMed          Journal:  Mucosal Immunol        ISSN: 1933-0219            Impact factor:   8.701


  66 in total

1.  ConceptMetab: exploring relationships among metabolite sets to identify links among biomedical concepts.

Authors:  Raymond G Cavalcante; Snehal Patil; Terry E Weymouth; Kestutis G Bendinskas; Alla Karnovsky; Maureen A Sartor
Journal:  Bioinformatics       Date:  2016-01-21       Impact factor: 6.937

2.  A common MUC5B promoter polymorphism and pulmonary fibrosis.

Authors:  Max A Seibold; Anastasia L Wise; Marcy C Speer; Mark P Steele; Kevin K Brown; James E Loyd; Tasha E Fingerlin; Weiming Zhang; Gunnar Gudmundsson; Steve D Groshong; Christopher M Evans; Stavros Garantziotis; Kenneth B Adler; Burton F Dickey; Roland M du Bois; Ivana V Yang; Aretha Herron; Dolly Kervitsky; Janet L Talbert; Cheryl Markin; Joungjoa Park; Anne L Crews; Susan H Slifer; Scott Auerbach; Michelle G Roy; Jia Lin; Corinne E Hennessy; Marvin I Schwarz; David A Schwartz
Journal:  N Engl J Med       Date:  2011-04-21       Impact factor: 91.245

3.  Lung Microbiota and Metabolites Collectively Associate with Clinical Outcomes in Milder Stage Chronic Obstructive Pulmonary Disease.

Authors:  Siddharth S Madapoosi; Charmion Cruickshank-Quinn; Kristopher Opron; John R Erb-Downward; Lesa A Begley; Gen Li; Igor Barjaktarevic; R Graham Barr; Alejandro P Comellas; David J Couper; Christopher B Cooper; Christine M Freeman; MeiLan K Han; Robert J Kaner; Wassim Labaki; Fernando J Martinez; Victor E Ortega; Stephen P Peters; Robert Paine; Prescott Woodruff; Jeffrey L Curtis; Gary B Huffnagle; Kathleen A Stringer; Russell P Bowler; Charles R Esther; Nichole Reisdorph; Yvonne J Huang
Journal:  Am J Respir Crit Care Med       Date:  2022-08-15       Impact factor: 30.528

4.  Altered miRNA expression in sputum for diagnosis of non-small cell lung cancer.

Authors:  Ying Xie; Nevins W Todd; Zhenqiu Liu; Min Zhan; Hongbin Fang; Hong Peng; Mohammed Alattar; Janaki Deepak; Sanford A Stass; Feng Jiang
Journal:  Lung Cancer       Date:  2009-05-14       Impact factor: 5.705

5.  The airway microbiome in patients with severe asthma: Associations with disease features and severity.

Authors:  Yvonne J Huang; Snehal Nariya; Jeffrey M Harris; Susan V Lynch; David F Choy; Joseph R Arron; Homer Boushey
Journal:  J Allergy Clin Immunol       Date:  2015-07-26       Impact factor: 10.793

6.  Host-Microbial Interactions in Idiopathic Pulmonary Fibrosis.

Authors:  Philip L Molyneaux; Saffron A G Willis-Owen; Michael J Cox; Phillip James; Steven Cowman; Michael Loebinger; Andrew Blanchard; Lindsay M Edwards; Carmel Stock; Cécile Daccord; Elisabetta A Renzoni; Athol U Wells; Miriam F Moffatt; William O C Cookson; Toby M Maher
Journal:  Am J Respir Crit Care Med       Date:  2017-06-15       Impact factor: 21.405

7.  Reagent and laboratory contamination can critically impact sequence-based microbiome analyses.

Authors:  Susannah J Salter; Michael J Cox; Elena M Turek; Szymon T Calus; William O Cookson; Miriam F Moffatt; Paul Turner; Julian Parkhill; Nicholas J Loman; Alan W Walker
Journal:  BMC Biol       Date:  2014-11-12       Impact factor: 7.431

8.  Randomised, double-blind, placebo-controlled trial with azithromycin selects for anti-inflammatory microbial metabolites in the emphysematous lung.

Authors:  Leopoldo N Segal; Jose C Clemente; Benjamin G Wu; William R Wikoff; Zhan Gao; Yonghua Li; Jane P Ko; William N Rom; Martin J Blaser; Michael D Weiden
Journal:  Thorax       Date:  2016-08-02       Impact factor: 9.139

Review 9.  Metabolomics and Its Application to Acute Lung Diseases.

Authors:  Kathleen A Stringer; Ryan T McKay; Alla Karnovsky; Bernadette Quémerais; Paige Lacy
Journal:  Front Immunol       Date:  2016-02-29       Impact factor: 7.561

10.  Critical Relevance of Stochastic Effects on Low-Bacterial-Biomass 16S rRNA Gene Analysis.

Authors:  Jeffrey L Curtis; Sara D Adar; John R Erb-Downward; Nicole R Falkowski; Jennifer C D'Souza; Lisa M McCloskey; Roderick A McDonald; Christopher A Brown; Kerby Shedden; Robert P Dickson; Christine M Freeman; Kathleen A Stringer; Betsy Foxman; Gary B Huffnagle
Journal:  mBio       Date:  2020-06-09       Impact factor: 7.867

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.